A Retinal Bet With Big-Pharma Muscle and Blackstone Financing
Johnson & Johnson (NYSE: JNJ) is putting substantial capital behind a straightforward proposition: better control of retinal disease, potentially with more time between treatments, would be worth bringing into its pharmaceutical portfolio. On…
A New Nasdaq Arrival With More Than a New Name
Biotechnology companies often arrive on Wall Street with an ambitious presentation and a conspicuously modest bank account. Mentari Therapeutics (Nasdaq: MTRI) has chosen a more substantial entrance. The Waltham, Massachusetts-based migraine-drug developer…
AlloSure Kidney Data Excites, Dupixent Sales Surge and POTENTIAL Competitor, EP-104GI, Nears December EoE Catalyst
Biotechnology’s most persuasive growth stories are moving beyond laboratory promise and into financial statements, clinical evidence and approaching trial milestones. CareDx (NASDAQ: CDNA) reported third-quarter revenue growth…
As SER-252 advances into its second dose cohort, Serina is building a case that improving how a medicine reaches patients can be as consequential as discovering the medicine itself.
Serina Therapeutics, Inc. (NYSE American: SER) is pursuing an appealing proposition in biotechnology:…
A pivotal trial victory, a growing dermatology franchise and an approaching oncology catalyst put IRON, ARQT and PBLS in the spotlight, while the BBC biotech ETF offers a broader view of the sector.
October 19, 2026
Biotechnology investors are being offered three…
A substantial takeover premium highlights the value of differentiated medicines, while Serina Therapeutics and Eupraxia Pharmaceuticals approach clinical milestones of their own.
October 19, 2026
Biotechnology investors received a rather emphatic reminder Monday that pharmaceutical innovation can still command a premium, even…
Clinical progress, a proposed U.S. research initiative and vaccine licensing economics strengthen the bull case.
Biotechnology investors are finding fresh reasons to look beyond the pandemic trade. Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX) and Merck (NYSE: MRK) rallied on October 9 as…
The Market’s Growth Engines Are Getting Physical
Wall Street has spent years rewarding promises around artificial intelligence, advanced medicine and space infrastructure. This week, the narrative acquired something investors usually appreciate even more: concrete evidence of execution. Bayer AG (OTC: BAYRY) is…
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a new layer of clinical durability to its EoE investment case, and Wall Street’s bullish coverage is becoming harder to overlook. The company’s latest 52-week EP-104GI data, including 64% clinical remission among evaluable higher-dose…
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…
